Objective The objective of this systematic review was to identify and assess the quality of published economic decision-analytic models within atopic eczema against best practice guidelines, with the intention of informing future decision-analytic models within this condition. Methods A systematic search of the following online databases was performed: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, NHS Economic Evaluation Database, EconLit, Scopus, Health Technology Assessment, Cost-Effectiveness Analysis Registry and Web of Science. Papers were eligible for inclusion if they described a decision-analytic model evaluating both the costs and benefits associated with an intervention or prevention for atopic eczema. Data were extracted using a standardised form by two independent reviewers, whilst quality was assessed using the modelspecific Philips criteria. Results Twenty-four models were identified, evaluating either preventions (n = 12) or interventions (n = 12): 14 reported using a Markov modelling approach, four utilised decision trees and one a discrete event simulation, whilst five did not specify the approach. The majority, 22 studies, reported that the intervention was dominant or cost effective, given the assumptions and analytical perspective taken. Notably, the models tended to be short-term (16 used a time horizon of B1 year), often providing little justification for the limited time horizon chosen. The methodological and reporting quality of the studies was generally weak, with only seven studies fulfilling more than 50% of their applicable Philips criteria. Conclusions This is the first systematic review of decision models in eczema. Whilst the majority of models reported favourable outcomes in terms of the cost effectiveness of the new intervention, the usefulness of these findings for decisionmaking is questionable. In particular, there is considerable scope for increasing the range of interventions evaluated, for improving modelling structures and reporting quality.
Introduction
Atopic eczema, also known as atopic dermatitis and from herein referred to as eczema, is a chronic disease characterised by dry, red, itchy skin, which sometimes blisters, Electronic supplementary material The online version of this article (doi:10.1007/s40273-017-0564-7) contains supplementary material, which is available to authorized users. weeps or crusts [1] . Eczema primarily affects children, with an onset in the first few months of life, although it can also be experienced in adulthood [2] . There is currently no cure for eczema, and thus treatments are twofold: to control the eczema during periods of remission and to treat the eczema when it becomes exacerbated. Individuals with eczema are likely to develop other atopic diseases such as asthma or allergic rhinitis; for example, it is estimated that 30% with eczema develop asthma and 35% develop allergic rhinitis [3] .
Alongside the physical symptoms, sufferers may also experience emotional stress, depression or sleep deprivation, resulting in a diminished quality of life [4] . In the UK, the lifetime prevalence of eczema is estimated to be between 12.5 and 20% [5, 6] . The annual personal cost for the UK population suffering with eczema, including the costs of purchasing over-the-counter preparations, special clothing or laundry detergents, as well as salary losses, has been estimated as £297 million (price year not stated) [7] . In comparison, the annual cost to the National Health Service (NHS) is estimated to be £125 million (price year not stated) [7] . These estimates, paired with the reduced quality of life of sufferers, indicate the importance of economic decision-making in this area.
There are currently no published reviews of decisionanalytic models pertaining to eczema. Therefore, this study aims to systematically identify and review such models, comparing their results and evaluating their strengths and limitations relative to the Philips criteria [8] , using the three broad categories of 'data', 'structure' and 'uncertainty and consistency'. In doing so, this study will act as a resource for decision makers and interested clinicians, signposting to existing models. It may also inform the development of future decision-analytic models within eczema, which may utilise any strengths and improve upon any weaknesses identified within this review.
Methods
The methods used within this systematic review have been developed and reported according to the suggested methods in ''Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015'' [9] .
Literature Search
A systematic search was conducted of the following electronic databases, from database inception to 22 May 2017: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, NHS Economic Evaluation Database, EconLit, Scopus, Health Technology Assessment, Cost-Effectiveness Analysis Registry and Web of Science. The complete protocol and search strategy is published elsewhere [10] , although key search terms included ''eczema'', ''dermatitis'', ''cost'', ''QALY'' and ''econ*''. In addition to the electronic search, the reference lists of review papers and eligible studies were inspected, and the authors of any relevant conference abstracts were, where possible, contacted. No restriction was made on the publication language within the electronic search.
Eligibility Criteria
As the electronic search strategy was used as part of a wider body of work [10] , it was designed to identify papers reporting primary data on cost and/or outcome (utility or willingness-to-pay) data on eczema. Thus, this systematic review reflects a subset of the results, with the additional eligibility criteria that a full economic evaluation be conducted using a decision-analytic modelling approach. In this instance, we defined a decision-analytic model to be a mathematical framework that uses data from multiple sources to evaluate the long-term costs and benefits of an intervention and its comparators, with the aim of informing decision-making [11, 12] . Despite the search strategy not being restricted by publication language, only papers in English were considered within the review.
Study Selection
Study selection occurred in two stages and was performed by two independent reviewers. Initially, the titles and abstracts of the search results were screened. Following this, the full papers of the potentially eligible abstracts were accessed and reviewed to determine inclusion within the review. Where disagreement occurred, a third reviewer was used.
A flow diagram of the systematic literature search and study selection can be found in Fig. 1 .
Data Extraction
Data extraction was carried out with the aim of capturing the main results and identifying key points about the decision-analytic model, these included, but were not limited to, type of model used, population studied, intervention evaluated, time horizon, and source of clinical and cost data.
Data were extracted using a standardised form, by two independent reviewers and, where disagreement occurred, resolution was sought through reviewer discussion. Where any clinical questions arose, these were discussed with a consultant dermatologist. Reporting quality was assessed using the detailed, decision-analytic model-specific, Philips criteria [8] . This criteria is commonly used to assess model quality in the existing literature [13] [14] [15] , and so was deemed the most appropriate to be used within this review.
The data extraction and quality assessment forms can be found in Electronic Supplementary Material 1.
Results
Results are presented using a narrative approach as it was not appropriate to synthesise the findings due to the heterogeneity of populations, interventions and comparators considered.
Description of Included Models
A total of 24 models, published between 1997 and 2016, were identified, the general characteristics of which are detailed in Table 1 . To facilitate comparison, studies are grouped into those evaluating preventions and interventions and, where possible, the same intervention. Also reported are the cost-effectiveness results using the original price year and currency, as well as an inflated result for a common price year (2016) and currency (UK pounds sterling [£]) using a web-based tool [16] . Where the price year was not stated, it was assumed, for the purposes of this estimate, to be the year of publication. Notably, some of the studies used the same decision model structure [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] to conduct analyses for different countries, whilst the same model was discussed in a health technology assessment Decision-analyƟc models (n = 24) This paper converted results into a common currency, Euros, without providing the exchange rate used. Thus to convert these results into 2016 prices, using UK pounds sterling, it was necessary to convert the prices back into the original country's currency, using the average exchange rate for the 2008 price year, sourced from the European Central Bank, using this value to then inflate and convert to 2016 UK pounds sterling prices using a web-based tool [16] Decision-Analytic Models in Atopic Eczema(HTA) monograph and within a journal article, albeit narrower in scope [27, 28] . Overall, it was judged that nine studies conducted costeffectiveness analyses [17, 18, [20] [21] [22] [23] [29] [30] [31] , 11 conducted cost-utility analyses [27, 28, [32] [33] [34] [35] [36] [37] [38] [39] [40] , three conducted both cost-effectiveness and cost-utility analyses [24] [25] [26] , and one carried out a cost-minimisation and costeffectiveness analysis [19] .
An equal number of studies evaluated preventions and treatments. Of those evaluating preventions for eczema, nine [17-20, 23-26, 31 ] evaluated partially hydrolysed formula milk, given to at-risk infants, where 'at-risk' was defined as having first-degree atopic heredity. The comparator for all but one of these studies was standard cows' milk formula, with one study [19] comparing with extensively hydrolysed formula milk instead. The remaining three papers considered a mixture of prebiotics [37] , oral application of bacterial lysate [30] and various prophylactic moisturisers, which included sunflower seed oil [40] . In comparison, studies of eczema treatments evaluated a wider range of interventions. Four evaluated tacrolimus ointment [21, 22, 34, 36] , three considered pimecrolimus ointment [27, 32, 33] , whilst Garside et al. [28] evaluated both tacrolimus and pimecrolimus. Three studies evaluated emollient or barrier preparations [35, 38, 39] . Finally, one Spanish study evaluated a topical corticosteroid preparation [29] . Notably, no modelling studies were found evaluating a broader range of interventions (e.g. education programmes, psychological therapy or different service configurations) beyond medications and formula milk.
Due to the large number of studies evaluating hydrolysed infant formulas, the most common population considered in 12 studies [17-20, 23-26, 30, 31, 37, 40] was infants at risk of developing eczema. A further four papers [27, 28, 32, 34] considered subjects of all ages, four [21, 29, 36, 39] considered ''patients'' with eczema without stating the age range, two studies [33, 38] considered paediatric patients and two studies [22, 35] looked solely at adults.
The most common decision-analytic approach was a Markov modelling process, used in 14 studies [21-28, 32, 33, 35-38] . Within these, the cycle length ranged from 1 week [25] to 1 year [37] , whilst four studies [21, 26, 32, 33] did not specify the cycle length used. A decision-tree was used in four studies [29] [30] [31] 40] , and only one study was found to use a discrete-event simulation model [39] . Five papers [17] [18] [19] [20] 34] did not explicitly state the methodology used, referring to a ''decision-analytic model'', although it could be inferred that a Markov modelling approach was used. The majority of studies (14) [ 17-22, 27, 28, 33-36, 38, 39] used a time horizon spanning a year, and most were reportedly conducted using a societal [23, 25, 26, 29, 35, 38, 39] or third-party payer [21, 22, 27, 28, 33, 34, 36, 37] perspective. Other studies report taking multiple perspectives, for example, two studies conducted analysis from both third-party and societal perspectives [31, 32] and four studies considered three different perspectives: the ministry of health, the subject's family and a societal perspective (which combined the two former perspectives) [17] [18] [19] [20] . Kiencke et al. [30] failed to report the perspective used and Bhanegaonkar et al. [24] reported to use the perspective of ''urban populations'' within their analyses.
It was found that 22 studies reported that the intervention was dominant or cost effective, given the assumptions made and the analytical perspective taken. Only two papers, evaluating tacrolimus [22] and pimecrolimus [27] in comparison to topical corticosteroids, found that the intervention evaluated was not cost effective. Reported incremental cost effectiveness ranged from US$353 [40] (equivalent to £246.39 in 2016 prices) per quality-adjusted life-year (QALY) gained, comparing petrolatum cream to usual care which in this case was seemingly no treatment, to US$40,000 [32] (equivalent to £34,728.01 in 2016 prices, assuming a price year of 2004) per QALY gained, comparing pimecrolimus ointment to usual therapy. A total of seven (29%) studies [17] [18] [19] [20] [23] [24] [25] were either partially or fully funded by the manufacturer of the evaluated product.
Quality Assessment
The Philips criteria [8] consists of 56 items intended to assess the reporting quality of decision models across three broad categories: 'structure', 'data' and 'uncertainty and consistency'. In this review, each item was answered using 'yes', 'no', 'partial' or 'not applicable'. A response of 'yes' indicated the question was appropriately answered, 'no' indicated it was not answered or not enough detail was given and 'partial' was used when only some elements of the criteria were satisfied. When an item was not relevant to the model, 'not applicable' was used. Electronic Supplementary Material 2 shows the responses given for each of the studies. These broad categories and the item responses form the basis of the following discussion.
Structure
It is important when constructing a model to decide which modelling approach to use, as different model types are best used in different circumstances [41] . However, a number of papers omitted justification for the modelling approach selected and only five papers [22, 25, 27, 28, 37] gave full or partial justification regarding the model structure. Of these, Ellis et al. [22] provided a comprehensive justification for using a Markov model, stating that ''it is able to represent more accurately the cyclic, recursive nature of AD. Markov models simulate how patients might experience periods of remission and recurrence, and treatment and response'', whilst also citing other published papers that used this modelling approach within other dermatological conditions. Only four papers explicitly discussed the implications of using alternative modelling structures [22, 27, 28, 37] . Overall, the selected modelling approaches were relatively similar, with the majority of studies using a Markov cohort approach, and fewer using decision-tree analysis. Interestingly, no studies used a whole disease modelling process [42] . Only one study used a discrete-event simulation [39] , although this was rudimentary, having only two health states, eczema and eczema-free, and using clinical data from a single randomised controlled trial. The lack of more complex modelling methods may indicate that a Markov approach is sufficient for modelling eczema, without the need for incorporating individual-level interaction. Alternatively, it could reflect an absence of appropriate data to inform a more complex model, as suggested by Pitt et al. [27] : ''An alternative modelling approach, such as discrete event simulation which could do justice to the conditional aspects of treatment might be preferred if such treatment pathway data for eczema were available''. In comparison to other similar dermatological conditions, such as psoriasis, there are a similarly limited number of modelling approaches used. Findings from a recent systematic review within psoriasis found only decision trees and Markov models [43] .
To evaluate the appropriateness of the modelling approach, the decision problem and objective of the evaluation should be described, which was clearly outlined by all but three [29, 39, 40] of the papers. In line with the stated objectives, for the majority of papers the costs and outcomes measured were also consistent with the perspectives taken. Where a third-party perspective was used, primarily the costs included were limited to the intervention and wider healthcare costs. By comparison, for studies taking a societal perspective, the range of costs included was more varied. Most common was the expected productivity losses associated with time off work, or time required to look after children, with this cost being included in 14 studies [17-20, 23-26, 29, 31, 32, 35, 38, 39] . Less frequently included were the transportation costs associated with visiting a physician, included in only six studies [17-20, 23, 24] , as well as the costs of over-thecounter medications [31, 32] , childcare costs [20] and the time taken to apply emollients [20] . Of the papers that took a societal perspective, Mertens et al. [31] took the most comprehensive view of costs, taking into account productivity losses, the cost of additional household expenses such as bed encasings and special diet, as well as any homeopathic treatments and over-the-counter medications required.
Only one of the studies was thought to have used an inappropriate modelling approach [37] , using the four health states of no eczema, eczema, no asthma and asthma, and stating that they were ''mutually exclusive''. These states are not mutually exclusive and therefore one of the requirements of a Markov model is violated [44] . A further nine studies [17-19, 29-32, 34, 40] provided insufficient detail to decide if the modelling approach was appropriate. Two studies, using decision trees, had relatively long time scales of 3 [30] and 6 years [31] , despite decision trees being recommended to consider short-term events [11] .
In models using a Markov process, the structure usually centred on progression through different treatment states [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Alternatively, eight studies used disease severity states [32] [33] [34] [35] [36] [37] [38] [39] . Of these, three studies [32, 33, 38] used the Investigator's Global Assessment (IGA) score for eczema [45] . The Harmonising Outcome Measures for Eczema (HOME) initiative [46] recommends using the Eczema Area and Severity Index (EASI) for clinician-reported signs of disease severity to facilitate comparison between trials. However, within the review, only two papers referred to the EASI. Abramovits et al. [21] calculated the percentage improvement using EASI scores at baseline and post-treatment defining a disease controlled day as [67% improvement, whilst Garside et al. [28] reported changes in EASI score within their effectiveness data.
Given these different approaches, the strengths and weaknesses of using either treatment or disease severity states should be considered; however, this evaluation was not found in the current literature. We consider that the use of treatment states would facilitate understanding by end users of the evaluation process, as the different treatment pathways are clearly displayed. It may also be easier to evaluate different pathways using this structure, for example in comparing the introduction of a therapy as firstline or second-line treatment, which within a severity state model would be harder to achieve. However, as disease severity is not included within treatment states, individuals within the same state are assumed to have the same utility and associated costs, despite potentially having different eczema severities, unless an adjunct is used. Garside et al. [28] and Pitt et al. [27] proposed a model within which treatment states are used along with a severity matrix for each state, which states the percentage with mild, moderate and severe eczema, allowing for different utilities to be assigned accordingly.
Weinstein et al. [47] suggested that the time horizon for analysis should capture all important benefits and consequences. Whilst eczema is not life limiting, patients can experience periods of remission or may develop the condition for the first time in adulthood [2] . Therefore, whilst a lifelong time horizon may not be necessary, characteristics of the condition indicate the need for an extended time period to be modelled. Moreover, the rationale of using a modelling approach is often to go beyond the limited time horizons of clinical trials [47] . Therefore, it is surprising that the majority of studies found within this review used only a 1-year time horizon [17-22, 27, 28, 33-36, 38, 39] , particularly when considering adults: for example, ''A shorter time horizon of 1 year was modelled; this duration was sufficient to capture the cyclical response and relapse characteristics of eczema'' [27] . In comparison, for paediatric populations, the shortest time horizon considered was 6 months (notably, this was a decision tree) [40] ranging to 16 years [37] , with the majority using a time horizon of 6 years [23-26, 30, 31] .
Of the models where it was applicable, very few papers adequately defined and justified the cycle length chosen [27, 36, 38] . More commonly, the cycle length was stated but not justified, with this occurring in ten of the studies [17-20, 23-25, 28, 35, 37] . For the six remaining studies, the cycle length used was either unclear or not explicitly stated, thus reducing the overall transparency of the models. For example, a cycle length of 1 year was used by Lenoir-Wijnkoop et al. [37] to evaluate a preventative infant formula, with no justification for this given. Given that the cycle length of any model should reflect the ''minimum interval over which pathology and symptoms is expected to alter'', [8] this is a weakness of the current literature. For the majority of models it was not applicable to apply a half-cycle correction, given the short cycle lengths chosen [48] . However, where it was applicable, very few papers discussed using a half-cycle correction or provided justification for why it had not been used. Ellis et al. [33] did report using a half-cycle correction, although the exact cycle length used was not explicitly stated [33] , whilst Pitt et al. [27] provided justification for not performing a half-cycle correction.
Data
Data sources were consistently underreported, particularly when describing how data were identified, which in 13 papers [21-26, 30, 31, 33, 35, 36, 38, 39] was not discussed. Moreover, the quality of the data was not assessed in 16 of the papers [20, 21, 23-27, 29, 30, 32, 33, 35-38, 40] . It was also found that of the papers that utilised the same model structure for evaluations in different countries [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , very few adaptations were made in terms of the data inputs or model structure. Largely, the only change that was made was to the unit cost sources and currency used, with the clinical data inputs remaining unchanged.
In addition to identified data, a large majority of studies used expert opinion to inform some aspect of the decisionanalytic model, with only five papers reporting no reliance on expert opinion [30, 33, 36, 39, 40] . Whilst it is not detrimental to use expert opinion, according to the hierarchy of evidence, as outlined by Cooper et al. [49] , it is advised that other data sources are consulted before resorting to expert opinion. However, by not stating how data were identified, it is unclear whether other sources, higher in the hierarchy, were overlooked or if there were simply no other data sources available.
Of the papers that did use expert opinion to inform parameters, the level of detail regarding how opinion was elicited was minimal, going against the reporting advice proposed by Leal et al. [50] . In some studies, the members of the clinical expert panel were not described, making it difficult to assess whether appropriate experts were used, or if their opinions were valid within the population group being studied. To demonstrate, Tang et al. [38] considered 12 different countries and relied heavily on expert opinion to inform transition probabilities as well as resource use, but failed to list the members of the expert panel and their expertise. Particularly when considering such a wide geographical area, it is especially important to provide detail of who the expert panel was, to enhance the transparency of assumptions made and to allow judgement of their validity. Three studies provided details on the experts used and the methods employed to elicit expert opinion, perhaps due to the sizable reliance on expert opinion within the developed models [17] [18] [19] , although they did not appear to follow formal elicitation methods [51] . The most common uses of expert opinion in the studies were to inform treatment pathways, approaches and discontinuation rates, as well as estimating levels of resource use across different eczema severity levels.
There were ten papers [23-25, 30, 31, 33, 34, 36, 39, 40 ] that used only one source of clinical data for treatment effects, only one of which provided justification, stating that only one trial was found in their literature search [33] . Of the papers that used more than one data source, the method of data synthesis was consistently underreported, with six papers [26, 27, 32, 35, 37, 38] providing little to no detail. In comparison, six studies used a meta-analysis to synthesise treatment effects [17-20, 22, 29] , ranked as the best source for eliciting clinical effects [49] whilst two [21, 28] were clear in providing the calculations and data sources used.
Of the 14 studies that conducted a cost-utility analysis, and thus included quality of life as an outcome measure, all but one, [34] , which utilised unpublished data, provided references to the source of the utility weights. One study [40] assumed the same utility values across all of the evaluated moisturisers, effectively making the inclusion of utilities redundant. Two studies were also judged to have included inappropriate utilities. Coyle and Barbeau [32] considered both an adult and paediatric population but sourced utilities based solely on a paediatric study, without discussing whether this was appropriate for an adult population. Similarly, Lenoir-Wijnkoop et al. [37] , considered a paediatric population, sourced utilities from a study by Poole et al. [52] which estimated health-related utilities with the EuoQol-5D (EQ-5D) by mapping responses from adults using the Short-Form-12 (SF-12). Using adult utilities amongst a paediatric population was justified by the authors, stating ''there is no evidence that utilities for children may be different from those for adults'', but neither does there appear to be any evidence to support the use of adult utilities amongst a paediatric population. Despite the other modelling studies using appropriate utilities, the method for deriving the utility weights was consistently underreported, and it was often necessary to consult referenced papers. Thus, this is one of the areas that future researchers could improve in the reporting of their models. One paper that did report this well, by Hjalte et al. [35] , considered the base-case utilities achieved by a Visual Analogue Scale (VAS) and used two different methods of derivation, time trade-off and standard gamble, within sensitivity analyses. Half of the utility studies referenced Stevens et al. [53] in some way. This study involved 150 members of the general population valuing ten of 16 possible health states using the standard gamble technique, a disease-specific preference-based instrument later referred to as the ADQoL (Atopic Dermatitis Quality of Life) [54] . Interestingly, these utility values have not yet been validated alongside a trial with another validated health-related quality-of-life instrument.
Uncertainty and Consistency
One of the main incentives for modelling is the ability to analyse the uncertainty surrounding a result [47] . Thus, it is suggested that sensitivity analysis is performed not only to assess the uncertainty in parameters used, but also for the methodological, structural and heterogeneity components [8] .
All papers considered some form of uncertainty within their model; however, none appeared to address all of the types of uncertainty identified above. Most consistently omitted was the assessment of both methodological and structural uncertainties.
Assessment of parameter uncertainty was generally well-completed, with the majority of papers performing at least a one-way sensitivity analysis. Moreover, 11 papers [17-20, 23-28, 34] reported performing probabilistic sensitivity analysis (PSA), arguably the most appropriate way to assess parameter uncertainty [55] . However, within these, the distributions used were often not justified, without which the usefulness of the analysis was reduced. Only seven papers [21, 29-31, 36, 37, 39] were judged not to have assessed parameter uncertainty appropriately. This was primarily due to not performing sensitivity analyses on all parameters and also not reporting the ranges used.
Uncertainty associated with heterogeneity was only assessed in four papers [27, 28, 34, 36] , which primarily involved looking at the results of the model according to different severities of eczema, as well as differences according to subgroups of the population.
When reporting the internal consistency of models, no study reported testing the mathematical logic of the model before use, as recommended by ISPOR (International Society for Pharmacoeconomics and Outcomes Research) [47] . The process of internal validation is key to enhancing the trustworthiness of results and ensuring the model is fit for purpose [56] . Similarly, between-model validation was only discussed in three papers [25, 26, 39] . For example, Bhanegaonkar et al. [25] presented contradictory results produced from the model and discussed why they may have arisen. There was also only one paper by Garside et al. [28] , who reported calibrating their model against independent data. In other models, stated comparisons were not made due to the model being the first of its kind to assess the certain intervention [18, 19] , and others [22-24, 31, 34] did compare some of the model outputs against existing literature, but not decision-analytic models. The remaining 13 studies [17, 20, 21, 27, 29, 30, 32, 33, [35] [36] [37] [38] 40] did not compare results or offer justification for why this did not occur.
Discussion
This review has demonstrated the variety of modelling approaches used within eczema, the majority being Markov models. Largely, it was found that the rationale for using a modelling approach as opposed to any other method of economic evaluation was not well-explored, especially given the limited time horizon used within many of the studies. Nor was justification for the modelling approach selected routinely outlined. As well as this, the associated advantages and disadvantages of using either treatment or disease states were not commonly discussed, despite having important implications in the modelling process. The treatment state models have the advantage of being more transparent, in that it is easy to see how a patient can progress through the model; however, with the development of new treatments and guidelines, it is likely that these models may quickly become outdated. Alternatively, in using disease states, it is unlikely that the disease process will drastically alter, although it may be more difficult for the reader to grasp how the interventions being modelled affect the transitions, and thus to appreciate the inner workings of the model. This systematic review is believed to be the first to review decision-analytic models within eczema. A sizeable number of models were identified, comparable to the number found in other reviews in different disease areas, for example 18 in Parkinson's disease [57] and 16 in lower-extremity artery disease [58] , indicating that eczema is certainly not an under-researched condition. However, the literature is small in contrast to the number of clinical trials available within eczema [59] and the range of interventions evaluated is also comparatively limited.
Future modelling studies should consider using routinely collected clinical data to inform parameters instead of relying on expert opinion alone. Where this is not feasible, it is important to provide sufficient detail on the methods of eliciting expert opinion, including who the experts are and how their opinion was elicited. The time horizon of future models should be extended and an effort should be made to evaluate a greater range of eczema interventions. There is also no common modelling approach currently being implemented, nor is there consensus on the best methodological approaches to take. Therefore, there is scope for future research to develop a consensus approach, where assumptions and modelling approaches are agreed upon by interested clinicians and expert modellers. This has in fact been carried out in other disease areas, such as rheumatoid arthritis, with the objective to ''assist model development and review to inform future policy decisions'' [60] . Having now identified all published models within eczema, a similar initiative could be implemented.
Whilst every effort was made to conduct this review in a systematic manner and according to published guidelines [9] , it is acknowledged that there are some limitations. For example, the search strategy only covered published research articles, and therefore it is possible that some guidance or policy documents relevant to this review may have been missed. As well as this, despite having two reviewers independently extracting data, when assessing the quality of the reporting, the decision as to whether criteria were satisfied was subject to individual interpretation of checklist items and the relative importance placed on each aspect within it. It is also acknowledged that due to strict journal word limits, it is often difficult for authors to include all relevant details of their modelling approach. However, with the increased ability to publish supplementary material, it is likely that in the future this difficulty will be reduced.
The Philips criteria [8] is frequently now used as the standard for assessing model reporting, but it was not developed to be used as a checklist and was written with a focus on cumulating all available evidence on reporting criteria. Several of the studies in this review were published before the Philips criteria [21, 22, 29] , thus it may be unfair to assess them based on current standards, given that modelling techniques have developed substantially since the original manuscripts were published. The Philips criteria have 56 assessment items, so the task of synthesising these for the included studies was challenging, meaning only a subset of items have been reported, although the detailed assessments can be viewed in Electronic Supplementary Material 2.
Conclusion
This review indicates that there are currently no models that satisfy the majority of points within the Philips criteria, showing there is scope for improvement. As a result of this review, it can be seen that any future model should consider a longer time horizon for both adults and children, in order to ensure that all relevant costs and benefits have been considered. Author Contributions EM contributed to the design of the study, carried out the searches, screening and data extraction, contributed to interpretation of data, and drafted and critically reviewed the paper. TS contributed to the design of the study, carried out the screening and data extraction, contributed to interpretation of data, and drafted and critically reviewed the paper. NL contributed to the design of the study and critically reviewed the paper.
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